- Dynamics of exchange parameters of hormonal indicators in patients with climacteric syndrome associated with diabetes type 2 under the influence of complex therapy with application of antihomotoxicological agents
Dynamics of exchange parameters of hormonal indicators in patients with climacteric syndrome associated with diabetes type 2 under the influence of complex therapy with application of antihomotoxicological agents
HEALTH OF WOMAN. 2018.5(131):36–39; doi 10.15574/HW.2018.131.36
Pavlovska M. O.
Bogomolets National Medical University, Kiev
The objective: was to compare the efficacy of complex methods of treating climacteric syndrome in patients with concomitant type 2 diabetes mellitus (DM) by analyzing hormonal parameters before and after complex therapy using antihomotoxicological drugs.
Materials and methods. We examined 58 patients aged 45-55 years with a climacteric syndrome on the background of a 2-type diabetes mellitus. Women of the 1st group (n = 28) received only basic therapy according to the National Consensus for the management of patients in menopause with concomitant DM of type 2. Women of the 2nd group (n = 30) were treated with antihomotoxicological drugs against the background of basic therapy.
Results. The proposed complexes positively influenced the hormonal state of patients, and also reduced the severity of climacteric syndrome and psychoemotional component. More effective was a complex that included antihomotoxicological agents, which is confirmed by the dynamics of hormonal parameters.
Conclusion. From the clinical point of view, the obtained results give grounds to recommend these complexes for the correction of hormonal disorders in women with menopausal disorders on the background of type 2 diabetes mellitus.
Key words: climacteric syndrome, diabetes type 2, base therapy, antihomotoxicological agents.
1. Andreeva EN, Grigoryan OG. 2017. Menopause with endocrinopathies (evidence base):40.
2. Leush SS, Oliinik YuV. 2006. Antihomotoxic therapy of gynecological diseases: methodical recommendations:30.
3. Gerasimovich EM. 2007. Modern view on the therapy of climacteric disorders 4: 84‒88.
4. Kononets AP. 2015. Bioregulation approach in the therapy of dyshormonal disorders in women 5: 122‒124.
5. Krasnikova NV, Shemetova GN. 2013. Comorbid pathology in women in menopause 2: 31‒35.
6. Manukhin IB, Taktarov VG, Shmeleva SV. 2015. Quality of life and menopause: 318.
7. Accker LV. 2010. Pathology of menopause: a guide for doctors: 439.
8. Pashchenko VN. 2010. Evidence base of antihomotoxic therapy 2:87.
9. About the approval of clinical protocols for obstetric and gynecological care: the order of the Ministry of Health of Ukraine dated 15.12.2003. 2003. 582:162.
10. Tatarchuk TF, Shevchuk TV. 2004. Complex antihomotoxic therapy of cephalalgic form of premenstrual syndrome 1:16-19.
11. Tatarchuk TF, Kosy NV, Samosiynaya OA. 2005. Treatment of climacteric syndrome in women with myoma of the uterus in perimenopause 2:130-133.
12. Tatarchuk TF, Kosei NV. 2001. Experience in the use of antihomotoxic drugs in the treatment of early climacteric disorders 2:33-37.
13. Yureneva SV. 2017. Modern approaches to the correction of menopausal disorders: 78.
14. Muka T, Asllanaj E, Avazverdi N. 2017. Age at natural menopause and risk of type 2 diabetes: a prospective cohort study 60;10:1951‒1960.
15. Lobo RA, Pickar JH, Stevenson JC. 2016. Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause 254:282‒290.
16. Deleruyelle LJ. 2017. Menopausal symptom relief and side effects experienced by women using compounded bioidentical hormone replacement therapy and synthetic conjugated equine estrogen and/or progestin hormone replacement therapy 3;21;1:6‒16.
17. Holloway D. 2018. Menopause symptom management in the United Kingdom 53;2:263‒277.
18. Karvonen-Gutierrez CA, Park SK, Kim C. 2016. Diabetes and menopause 16;4. Art. 20.
19. Ţiţ DM, Pallag A, Iovan C. 2017. Somatic-vegetative symptoms evolution in postmenopausal women treated with phytoestrogens and hormone replacement therapy 46;11:1528‒1534.
20. Stuenkel CA. 2017. Menopause, hormone therapy and diabetes 20;1:11‒21.
21. Monterrosa-Castro A, Blümel JE, Portela-Buelvas K. Type II diabetes mellitus and menopause: a multinational study 16;6:663‒672.